Mortality rates among carriers of ataxia-telangiectasia mutant alleles

Annals of Internal Medicine

Volumn 133, Issue 10, 2000, Pages

  Su, Y ^a   Swift, M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALLELISM; ARTICLE; ATAXIA TELANGIECTASIA; AUTOSOMAL RECESSIVE DISORDER; CANCER RISK; CARDIOVASCULAR RISK; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC RISK; HETEROZYGOTE DETECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0034700243     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-133-10-200011210-00009     Document Type: Article

References (57)

1. Genetic aspects of ataxia telangiectasia
2. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia
3. The incidence and gene frequency of ataxia-telangiectasia in the United States
4. Heterozygous ATM mutations do not contribute to early onset of breast cancer
5. Malignant neoplasms in the families of patients with ataxia-telangiectasia
6. Breast and other cancers in families with ataxia-telangiectasia
7. Cancer predisposition of ataxia-telangiectasia heterozygotes
8. Incidence of cancer in 161 families affected by ataxia-telangiectasia
9. Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain
10. Breast cancer and other cancers in Norwegian families with ataxia-telangiectasia
11. Cancer and cardiac deaths in obligatory ataxia-telangiectasta heterozygotes
12. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer
13. An allelic variant at the ATM locus is implicated in breast cancer susceptibility
14. Breast cancer risk in ataxia-telangiectasia (AT) heterozygotes: Haplotype study in French AT families
15. A single ataxia telangiectasia gene with a product similar to PI-3 kinase
16. Mutations associated with variant phenotypes in ataxia-telangiectasia
17. Nonparametric estimation from incomplete observa tions
18. Exact permutational tests for group sequential clinical trials
19. Regression models and life-tables (with discussion)
20. Multivariate failure time data and competing risks
21. Accuracy of death certificates for coding coronary heart disease as the cause of death
22. Likelihood construction and further results on the proportional hazards model
23. Estimating Cox regression models with proc phreg
24. Miscellaneous topics
25. Competing risks
26. Proportional hazards model with covariates subject to measure ment error
27. Colorectal cancer deaths as determined by expert committee and from death certificate: A comparison. The Minnesota Study
28. The role of ataxia-telangiectasia heterozygotes in familial breast cancer
29. Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer
30. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene
31. Ataxia-telangiectasia: Identification and detection of founder-effect mutations in the ATM gene in ethnic populations
32. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia
33. Cancer risk in ATM heterozygotes: A model of phenotypic and mechanistic differences between missense and truncat ing mutations
34. The ATM gene and susceptibility to breast cancer: Analysis of 38 breast tumors reveals no evidence for mutation
35. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer
36. AT-tributable risks?
37. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: Expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer
38. Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia
39. ATM heterozygous germline mutations contribute to breast cancer-susceptibility
40. Frequent splicing mutation of the ATM gene in breast cancer
41. Association of an ATM missense substitution (S707P) with breast cancer
42. ATM mutations in breast cancer patients with early-onset or family history
43. Cancers in 44 families with ataxia-telangi ectasia
44. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species
45. ATM: The p53 booster
46. p53 and ATM: Cell cycle, cell death, and cancer
47. Requirement of ATM-dependent phosphorylation of brcal in the DNA damage response to double-strand breaks
48. International Commission for Protection Against Environmental Mutagens and Carcinogens. ICPEMC Working Paper 7/1/2. Shared risk factors for cancer and atherosclerosis - A review of the epidemiological evidence
49. Cellular radiosensitivity, radioresistant DNA synthesis, and defect in radioinduction of p53 in fibroblasts from atherosclerosis patients
50. Diversity of ATM gene mutations detected in patients with ataxia-telangiectasia
51. Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A-T patients
52. Scanning by DOVAM-S detects all unique sequence changes in blinded analyses: Evidence that the scanning conditions are generic